ライノウイルス感染症治療薬の世界市場レポート 2025年

ライノウイルス感染症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.9％で19億3,000万米ドルに成長します。予測期間中に予測される成長は、抗ウイルス薬への投資の増加、標的治療薬への需要の高まり、呼吸器疾患の有病率の増加、新興市場におけるヘルスケアアクセスの拡大、生物製剤とモノクローナル抗体の使用の高まりに起因しています。この期間の主な動向には、抗ウイルス剤研究の進展、ワクチン研究の進展、生物製剤とモノクローナル抗体の技術革新、広域スペクトル抗ウイルス剤の開発、ドラッグデリバリーのためのナノテクノロジーの進歩などがあります。

呼吸器疾患の有病率の増加は、ライノウイルス感染症治療薬市場の拡大を促進すると予想されます。呼吸器疾患は、喘息、慢性閉塞性肺疾患（COPD）、肺炎など、肺や気道に影響を及ぼし、呼吸を困難にする病状です。これらの疾患の増加は、主に大気汚染の増加や職業上の危険への曝露によるもので、特に脆弱な集団において、喘息、COPD、肺炎などの症状の一因となっています。ライノウイルス感染症治療薬は、ウイルス複製を標的とし、炎症を抑え、症状を緩和することによって呼吸器の健康をサポートし、最終的には呼吸機能を改善します。例えば、2023年11月、オーストラリア国立喘息評議会は、2022年にオーストラリアでは467人の喘息関連死が記録され、2021年の355人から増加したと報告しました。呼吸器疾患の罹患率の上昇に伴い、ライノウイルス感染症治療薬の需要は伸び続けています。

ライノウイルス感染症治療薬市場の主要企業は、治療効果を高め、症状の重篤度を軽減し、患者の回復を早めるための革新的な抗ウイルス治療薬の開発に注力しています。抗ウイルス薬は、体内でのウイルスの複製を阻害することでウイルス感染を治療します。これらの薬剤は、インフルエンザ、HIV、肝炎、ライノウイルスなど、さまざまなウイルスに有効です。抗ウイルス薬の中には、ウイルスが宿主細胞に侵入するのを阻止するものもあれば、ウイルスの複製や集合を阻止するものもあります。例えば、2025年3月、米国のバイオテクノロジー企業であるアルテサ・バイオサイエンシズ社は、COPD患者のライノウイルス感染症を治療する経口広域抗ウイルス薬バペンダビルの治験新薬（IND）申請を米国食品医薬品局（FDA）から承認されました。バペンダビルは、ライノウイルスがヒト細胞内に侵入して複製するのを阻害することにより作用し、ライノウイルスおよびその他の呼吸器系エンテロウイルスの97%に対して有効性を示しています。アルテサはバペンダビルの開発、製造、商品化に関する独占的な世界的権利を有しており、COPDや喘息を含むハイリスク集団に標的治療を提供することを目指しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ライノウイルス感染症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のライノウイルス感染症治療薬市場：成長率分析
• 世界のライノウイルス感染症治療薬市場の実績：規模と成長, 2019-2024
• 世界のライノウイルス感染症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ライノウイルス感染症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のライノウイルス感染症治療薬市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ウイルス薬
• 免疫調節薬
• ワクチン
• 鼻スプレー
• 対症療法
• 世界のライノウイルス感染症治療薬市場患者の年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳児
• 子供
• 大人
• お年寄り
• 世界のライノウイルス感染症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 鼻腔内
• 注射剤
• 世界のライノウイルス感染症治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 風邪
• 喘息の悪化
• 慢性閉塞性肺疾患（COPD）の増悪
• その他の適応症
• 世界のライノウイルス感染症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 専門薬局
• 世界のライノウイルス感染症治療薬市場抗ウイルス薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレコナリル
• バペンダビル
• ルピントリビル
• その他の抗ウイルス薬
• 世界のライノウイルス感染症治療薬市場免疫調節剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターフェロン
• Toll様受容体作動薬
• その他の免疫調節剤
• 世界のライノウイルス感染症治療薬市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化ワクチン
• 不活化ワクチン
• 組み換えワクチン
• 世界のライノウイルス感染症治療薬市場鼻スプレーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ヒスタミン点鼻スプレー
• 鼻づまり解消スプレー
• ステロイド点鼻スプレー
• 生理食塩水鼻スプレー
• 世界のライノウイルス感染症治療薬市場対症療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鎮痛剤
• 解熱剤
• 咳止め薬
• 去痰薬
• 抗ヒスタミン薬

第7章 地域別・国別分析

• 世界のライノウイルス感染症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のライノウイルス感染症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ライノウイルス感染症治療薬市場：競合情勢
• ライノウイルス感染症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • BioFire Diagnostics LLC Overview, Products and Services, Strategy and Financial Analysis
  • hVIVO Services Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Romark Laboratories L.C.
• Cocrystal Pharma Inc.
• Altamira Therapeutics Ltd.
• Biota Pharmaceuticals Inc.
• Aditum Bio Management Company LLC
• MetP Pharma AG
• Via Nova Therapeutics Inc.
• Maxwell Biosciences Inc.
• Altesa BioSciences Inc.
• Apollo Therapeutics Group Limited
• AIM ImmunoTech Inc.
• Bakar Labs
• Ntvirin Pharma
• bioRxiv
• Pneumagen Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ライノウイルス感染症治療薬市場2029：新たな機会を提供する国
• ライノウイルス感染症治療薬市場2029：新たな機会を提供するセグメント
• ライノウイルス感染症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A rhinovirus infection drug is a pharmaceutical agent designed to prevent, treat, or manage infections caused by rhinoviruses, the primary cause of the common cold. These drugs work by inhibiting viral replication, blocking the virus's entry into host cells, or modulating the immune response to reduce symptom severity and shorten the infection's duration.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main products used for rhinovirus infections include antivirals, immunomodulators, vaccines, nasal sprays, and symptomatic treatments. Antiviral drugs specifically target the virus to reduce infection severity and duration, contributing to market growth driven by pharmaceutical advancements. These drugs are administered to various patient age groups, including infants, children, adults, and the elderly, using different routes such as oral, intranasal, and injectable. They are used for indications such as the common cold, asthma exacerbations, chronic obstructive pulmonary disease (COPD) exacerbations, and other related conditions. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

The rhinovirus infections drug market research report is one of a series of new reports from The Business Research Company that provides rhinovirus infections drug market statistics, including the rhinovirus infections drug global market size, regional shares, competitors with the rhinovirus infections drug market share, detailed rhinovirus infections drug market segments, market trends, and opportunities, and any further data you may need to thrive in the rhinovirus infections drug. This rhinovirus infections drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rhinovirus infections drug market size has grown strongly in recent years. It will grow from $1.26 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth observed during the historic period can be attributed to the increasing prevalence of the common cold, greater awareness about respiratory infections, rising demand for over-the-counter medications, higher healthcare expenditure, and the growing adoption of combination therapies.

The rhinovirus infections drug market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth projected during the forecast period can be attributed to rising investments in antiviral drugs, a growing demand for targeted therapies, an increasing prevalence of respiratory disorders, expanding healthcare access in emerging markets, and the rising use of biologics and monoclonal antibodies. Key trends during this period include advancements in antiviral research, progress in vaccine research, innovation in biologics and monoclonal antibodies, the development of broad-spectrum antivirals, and advancements in nanotechnology for drug delivery.

The growing prevalence of respiratory disorders is anticipated to drive the expansion of the rhinovirus infections drug market. Respiratory disorders are medical conditions that affect the lungs and airways, making breathing difficult, such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The rise in these disorders is mainly due to increased air pollution and exposure to occupational hazards, which contribute to conditions such as asthma, COPD, and pneumonia, particularly in vulnerable populations. Rhinovirus infection drugs support respiratory health by targeting viral replication, reducing inflammation, and alleviating symptoms, ultimately improving respiratory function. For example, in November 2023, the National Asthma Council of Australia reported that in 2022, Australia recorded 467 asthma-related deaths, an increase from 355 deaths in 2021. As the incidence of respiratory disorders rises, the demand for rhinovirus infections drugs continues to grow.

Leading companies in the rhinovirus infections drug market are focused on developing innovative antiviral treatments to improve treatment effectiveness, lessen symptom severity, and speed up recovery for patients. Antiviral drugs treat viral infections by inhibiting the replication of viruses within the body. These drugs are effective against a range of viruses, including influenza, HIV, hepatitis, and rhinovirus. Some antivirals prevent the virus from entering host cells, while others block viral replication or assembly. For instance, in March 2025, Altesa BioSciences Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir, an oral broad-spectrum antiviral to treat rhinovirus infections in individuals with COPD. Vapendavir works by preventing the rhinovirus from entering and replicating in human cells and has shown effectiveness against 97% of rhinoviruses and other respiratory enteroviruses. Altesa holds exclusive global rights to develop, manufacture, and commercialize vapendavir, aiming to provide targeted treatment for high-risk populations, including those with COPD and asthma.

In September 2022, RIGImmune Inc., a US-based preclinical-stage biopharmaceutical company, acquired Subintro for an undisclosed amount. This acquisition enhances RIGImmune's development of stem-loop RNA therapeutics (SLRs), designed to activate the RIG-I innate immune sensor, which may improve the treatment and prevention of viral respiratory diseases. Subintro, a UK-based biotechnology company, specializes in antiviral therapeutics targeting respiratory diseases caused by RNA viruses, such as influenza, RSV, rhinovirus, and SARS-CoV-2.

Major players in the rhinovirus infections drug market are Pfizer Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., BioFire Diagnostics LLC, hVIVO Services Limited, Romark Laboratories L.C., Cocrystal Pharma Inc., Altamira Therapeutics Ltd., Biota Pharmaceuticals Inc., Aditum Bio Management Company LLC, MetP Pharma AG, Via Nova Therapeutics Inc., Maxwell Biosciences Inc., Altesa BioSciences Inc., Apollo Therapeutics Group Limited, AIM ImmunoTech Inc., Bakar Labs, Ntvirin Pharma, bioRxiv, Pneumagen Ltd.

North America was the largest region in the rhinovirus infection drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rhinovirus infections drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rhinovirus infections drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rhinovirus infections drug market consists of sales of decongestants, antihistamines, and pain relievers and fever reducers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rhinovirus Infections Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rhinovirus infections drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rhinovirus infections drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rhinovirus infections drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Antivirals; Immunomodulators; Vaccines; Nasal Sprays; Symptomatic Treatments
• 2) By Patient Age Group: Infants; Children; Adults; Elderly
• 3) By Route Of Administration: Oral; Intranasal; Injectable
• 4) By Indication: Common Cold; Asthma Exacerbation; Chronic Obstructive Pulmonary Disease (COPD) Exacerbation; Other Indications
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
• Subsegments:
• 1) By Antivirals: Pleconaril; Vapendavir; Rupintrivir; Other Antivirals
• 2) By Immunomodulators: Interferons; Toll-Like Receptor Agonists; Other Immunomodulators
• 3) By Vaccines: Live Attenuated Vaccines; Inactivated Vaccines; Recombinant Vaccines
• 4) By Nasal Sprays: Antihistamine Nasal Sprays; Decongestant Nasal Sprays; Steroid Nasal Sprays; Saline Nasal Sprays
• 5) By Symptomatic Treatments: Analgesics; Antipyretics; Cough Suppressants; Expectorants; Antihistamines
• Companies Mentioned: Pfizer Inc.; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; BioFire Diagnostics LLC; hVIVO Services Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rhinovirus Infections Drug Market Characteristics

3. Rhinovirus Infections Drug Market Trends And Strategies

4. Rhinovirus Infections Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rhinovirus Infections Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rhinovirus Infections Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rhinovirus Infections Drug Market Growth Rate Analysis
• 5.4. Global Rhinovirus Infections Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rhinovirus Infections Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rhinovirus Infections Drug Total Addressable Market (TAM)

6. Rhinovirus Infections Drug Market Segmentation

• 6.1. Global Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antivirals
• Immunomodulators
• Vaccines
• Nasal Sprays
• Symptomatic Treatments
• 6.2. Global Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infants
• Children
• Adults
• Elderly
• 6.3. Global Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intranasal
• Injectable
• 6.4. Global Rhinovirus Infections Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Common Cold
• Asthma Exacerbation
• Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
• Other Indications
• 6.5. Global Rhinovirus Infections Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies
• 6.6. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pleconaril
• Vapendavir
• Rupintrivir
• Other Antivirals
• 6.7. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferons
• Toll-like Receptor Agonists
• Other Immunomodulators
• 6.8. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• 6.9. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Nasal Sprays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihistamine Nasal Sprays
• Decongestant Nasal Sprays
• Steroid Nasal Sprays
• Saline Nasal Sprays
• 6.10. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Symptomatic Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Antipyretics
• Cough Suppressants
• Expectorants
• Antihistamines

7. Rhinovirus Infections Drug Market Regional And Country Analysis

• 7.1. Global Rhinovirus Infections Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rhinovirus Infections Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rhinovirus Infections Drug Market

• 8.1. Asia-Pacific Rhinovirus Infections Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rhinovirus Infections Drug Market

• 9.1. China Rhinovirus Infections Drug Market Overview
• 9.2. China Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rhinovirus Infections Drug Market

• 10.1. India Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rhinovirus Infections Drug Market

• 11.1. Japan Rhinovirus Infections Drug Market Overview
• 11.2. Japan Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rhinovirus Infections Drug Market

• 12.1. Australia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rhinovirus Infections Drug Market

• 13.1. Indonesia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rhinovirus Infections Drug Market

• 14.1. South Korea Rhinovirus Infections Drug Market Overview
• 14.2. South Korea Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rhinovirus Infections Drug Market

• 15.1. Western Europe Rhinovirus Infections Drug Market Overview
• 15.2. Western Europe Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rhinovirus Infections Drug Market

• 16.1. UK Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rhinovirus Infections Drug Market

• 17.1. Germany Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rhinovirus Infections Drug Market

• 18.1. France Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rhinovirus Infections Drug Market

• 19.1. Italy Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rhinovirus Infections Drug Market

• 20.1. Spain Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rhinovirus Infections Drug Market

• 21.1. Eastern Europe Rhinovirus Infections Drug Market Overview
• 21.2. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rhinovirus Infections Drug Market

• 22.1. Russia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rhinovirus Infections Drug Market

• 23.1. North America Rhinovirus Infections Drug Market Overview
• 23.2. North America Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rhinovirus Infections Drug Market

• 24.1. USA Rhinovirus Infections Drug Market Overview
• 24.2. USA Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rhinovirus Infections Drug Market

• 25.1. Canada Rhinovirus Infections Drug Market Overview
• 25.2. Canada Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rhinovirus Infections Drug Market

• 26.1. South America Rhinovirus Infections Drug Market Overview
• 26.2. South America Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rhinovirus Infections Drug Market

• 27.1. Brazil Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rhinovirus Infections Drug Market

• 28.1. Middle East Rhinovirus Infections Drug Market Overview
• 28.2. Middle East Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rhinovirus Infections Drug Market

• 29.1. Africa Rhinovirus Infections Drug Market Overview
• 29.2. Africa Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rhinovirus Infections Drug Market Competitive Landscape And Company Profiles

• 30.1. Rhinovirus Infections Drug Market Competitive Landscape
• 30.2. Rhinovirus Infections Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioFire Diagnostics LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. hVIVO Services Limited Overview, Products and Services, Strategy and Financial Analysis

31. Rhinovirus Infections Drug Market Other Major And Innovative Companies

• 31.1. Romark Laboratories L.C.
• 31.2. Cocrystal Pharma Inc.
• 31.3. Altamira Therapeutics Ltd.
• 31.4. Biota Pharmaceuticals Inc.
• 31.5. Aditum Bio Management Company LLC
• 31.6. MetP Pharma AG
• 31.7. Via Nova Therapeutics Inc.
• 31.8. Maxwell Biosciences Inc.
• 31.9. Altesa BioSciences Inc.
• 31.10. Apollo Therapeutics Group Limited
• 31.11. AIM ImmunoTech Inc.
• 31.12. Bakar Labs
• 31.13. Ntvirin Pharma
• 31.14. bioRxiv
• 31.15. Pneumagen Ltd.

32. Global Rhinovirus Infections Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rhinovirus Infections Drug Market

34. Recent Developments In The Rhinovirus Infections Drug Market

35. Rhinovirus Infections Drug Market High Potential Countries, Segments and Strategies

• 35.1 Rhinovirus Infections Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rhinovirus Infections Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rhinovirus Infections Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34955_Rhinovirus_Infections_Drug_GMR_2025